ERS 2021: NVALT 17 Suggests Possible Benefit of Adding Cisplatin-Pemetrexed to First-Line Erlotinib for Non–Small Cell Lung Cancer
Low study power and high treatment toxicity means search for better combination tyrosine kinase inhibitor treatments will continue
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.